PITTSBURGH, April 12, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application (ANDA) for Fexofenadine Hydrochloride Tablets, 30mg, 60mg and 180mg. Fexofenadine Hydrochloride Tablets are the AB-rated generic equivalent of Aventis Pharmaceuticals' Allegra^® Tablets, which had annual U.S. sales of approximately $1.4 billion as of December 31, 2005, according to IMS Health

About Mylan Laboratories

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit http://www.mylan.com.

SOURCE Mylan Laboratories Inc.

Media, Patrick Fitzgerald, or Investors, Kris King, both of Mylan Laboratories Inc., +1-724-514-1800